- Home
- MTEN vs CGTX Comparison
MTEN vs CGTX Comparison
Compare MTEN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTEN | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 158.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTEN | CGTX |
|---|---|---|
| Price | $0.90 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 138.0K | ★ 942.9K |
| Earning Date | 10-01-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,735,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $0.80 | $0.22 |
| 52 Week High | $26.03 | $3.83 |
Technical Indicators
Market Signals| Indicator | MTEN | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 17.49 | 53.10 |
| Support Level | $0.80 | $1.69 |
| Resistance Level | $1.26 | $1.77 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 9.54 | 75.58 |
Price Performance
Historical ComparisonAbout MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.